Study of FTY720 in Patients With Uveitis
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 5/3/2014 |
| Start Date: | September 2013 |
| End Date: | April 2014 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | 1-888-669-6682 |
A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis
This study will assess the safety, tolerability, and efficacy of FTY720 in patients with
acute, noninfectious intermediate, posterior and pan uveitis
acute, noninfectious intermediate, posterior and pan uveitis
Inclusion Criteria:
- Acute noninfectious posterior, intermediate, or pan uveitis
- Vitreous haze score of 1+ or more in the study eye at screening and baseline visits
Exclusion Criteria:
- Vaso-occlusive vasculitis involving the retinal macula
- Behçet's uveitis
- Patients requiring corticosteroid or another systemic immunosuppressive medication
for any other disease (e.g., asthma or some other autoimmune disease) that would
contraindicate tapering (topical steroids permitted)
- Other protocol defined inclusions and/or exclusions may apply.
We found this trial at
1
site
Click here to add this to my saved trials
